(Q46815520)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18185019%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

title

Cost consequences of adjuvant capecitabine, Mayo Clinic and de Gramont regimens for stage III colon cancer in the French setting (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18185019%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18185019%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

author name string

J Y Douillard

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18185019%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

P Tilleul

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18185019%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

P Dufour

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18185019%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

G Perrocheau

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18185019%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

J F Seitz

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18185019%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

P Maes

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18185019%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

A Lafuma

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18185019%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

F Husseini

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18185019%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

publication date

1 January 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18185019%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18185019%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

volume

72

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18185019%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

issue

3-4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18185019%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

page(s)

248-254

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18185019%20AND%20SRC:MED&resulttype=core&format=json

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

31 December 2019

cites work

1 reference

Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials

21 January 2018

1 reference

Capecitabine as adjuvant treatment for stage III colon cancer

21 January 2018

1 reference

Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial.

21 January 2018

1 reference

Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000113016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18185019%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference